The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | A Phase I trial of voruciclib +/- venetoclax for the treatment of NHL and AML
Alexey Danilov, MD, PhD, City of Hope, Duarte, CA, introduces a Phase I trial (NCT03547115) assessing voruciclib, a potent CDK9 inhibitor (CDK9i), alone or combined with venetoclax in patients with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL) or acute myeloid leukemia (AML). Findings from the ongoing trial demonstrate encouraging preliminary efficacy and safety, with no significant myelosuppression being observed. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: MEI, Lilly Oncology, Nurix, Abbvie, Beigene, Janssen, Astra Zeneca, Bristol Meyers Squibb, Genentech, GenMab, Merck
Research Funding: MEI, Lilly Oncology, Cyclacel, Bayer, Nurix, Abbvie, Beigene, Astra Zeneca, Bristol Meyers Squibb, GenMab
